Abstracts of the 26th Annual Conference of APASL, February 15–19, 2017, Shanghai, China

Abstracts of the 26th Annual Conference of APASL, February 15–19, 2017, Shanghai, China Hepatol Int (2017) 11 (Suppl 1):S1–S1093 DOI 10.1007/s12072-016-9783-9 AB STRACTS Abstracts of the 26th Annual Conference of APASL, February 15–19, 2017, Shanghai, China Asian Pacific Association for the Study of the Liver 2017 achieved by 100% (7/7) of patients with prior PI failure; 100% (42/42) Plenary Presentation with HCV/HIV coinfection; 91% (63/69) with advanced fibrosis (in- cludes 3 PI failures, 10 coinfections, 12 post-transplant); 90% (54/60) 17 February 2017 (Friday) with cirrhosis (includes 4 coinfections); 91% (20/22) post-liver trans- Plenary Presentation 01 plant, and 100% (125/125) with no/mild fibrosis. By HCV genotype, 15:45–17:15 98% (49/50) with GT-1b, 93% (13/14) with GT-2, 94% (179/190) with GT-3, and a single patient with GT-6 achieved SVR. Baseline NS5A RAS were detected in 13% (33/257) of patients. SVR was achieved in 85% (28/33) of patients with NS5A RAS: 100% (6/6) GT-1b patients PL001 with L31 M or Y93H, 75% (3/4) GT-2 with L31 M, 82% (18/22) of GT- 3 with A30 K or Y93H (including all of 8 with no/mild fibrosis), and in Impact of baseline NS5A polymorphisms on sustained virologic the single GT-6 patient with R30S. NS5A RAS were detected at relapse response rates to treatment with daclatasvir plus sofosbuvir in all http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Hepatology International Springer Journals

Abstracts of the 26th Annual Conference of APASL, February 15–19, 2017, Shanghai, China

Abstracts of the 26th Annual Conference of APASL, February 15–19, 2017, Shanghai, China

Hepatol Int (2017) 11 (Suppl 1):S1–S1093 DOI 10.1007/s12072-016-9783-9 AB STRACTS Abstracts of the 26th Annual Conference of APASL, February 15–19, 2017, Shanghai, China Asian Pacific Association for the Study of the Liver 2017 achieved by 100% (7/7) of patients with prior PI failure; 100% (42/42) Plenary Presentation with HCV/HIV coinfection; 91% (63/69) with advanced fibrosis (in- cludes 3 PI failures, 10 coinfections, 12 post-transplant); 90% (54/60) 17 February 2017 (Friday) with cirrhosis (includes 4 coinfections); 91% (20/22) post-liver trans- Plenary Presentation 01 plant, and 100% (125/125) with no/mild fibrosis. By HCV genotype, 15:45–17:15 98% (49/50) with GT-1b, 93% (13/14) with GT-2, 94% (179/190) with GT-3, and a single patient with GT-6 achieved SVR. Baseline NS5A RAS were detected in 13% (33/257) of patients. SVR was achieved in 85% (28/33) of patients with NS5A RAS: 100% (6/6) GT-1b patients PL001 with L31 M or Y93H, 75% (3/4) GT-2 with L31 M, 82% (18/22) of GT- 3 with A30 K or Y93H (including all of 8 with no/mild fibrosis), and in Impact of baseline NS5A polymorphisms on sustained virologic the single GT-6 patient with R30S. NS5A RAS were detected at relapse response rates to treatment with daclatasvir plus sofosbuvir in all 13 virologic failures while no NS5B RAS were detected. with or without ribavirin in patients infected with HCV genotypes Conclusion: In this retrospective sub-analysis, high SVR rates prevalent in Asia (90–100%) were observed after treatment with DCV + SOF ± RBV in challenging-to-treat patient populations infected with HCV genotypes 1 1 Fiona McPhee , Dennis Hernandez , Maria Jesus frequently observed in Asia. SVR rates (75–100%) were minimally 2 1 1 Jimenez-exposito , Eugene Scott Swenson , Nannan Zhou impacted in the few patients with BL RAS, irrespective of genotype. 1 2 Emergent NS5A RAS and no NS5B RAS were observed in patients not Bristol-Myers Squibb, Wallingford, CT, USA;...
Loading next page...
 
/lp/springer_journal/abstracts-of-the-26th-annual-conference-of-apasl-february-15-19-2017-TA8Gd8aJ0P
Publisher
Springer India
Copyright
Copyright © 2017 by Asian Pacific Association for the Study of the Liver
Subject
Medicine & Public Health; Hepatology; Colorectal Surgery; Surgery
ISSN
1936-0533
eISSN
1936-0541
D.O.I.
10.1007/s12072-016-9783-9
Publisher site
See Article on Publisher Site

Abstract

Hepatol Int (2017) 11 (Suppl 1):S1–S1093 DOI 10.1007/s12072-016-9783-9 AB STRACTS Abstracts of the 26th Annual Conference of APASL, February 15–19, 2017, Shanghai, China Asian Pacific Association for the Study of the Liver 2017 achieved by 100% (7/7) of patients with prior PI failure; 100% (42/42) Plenary Presentation with HCV/HIV coinfection; 91% (63/69) with advanced fibrosis (in- cludes 3 PI failures, 10 coinfections, 12 post-transplant); 90% (54/60) 17 February 2017 (Friday) with cirrhosis (includes 4 coinfections); 91% (20/22) post-liver trans- Plenary Presentation 01 plant, and 100% (125/125) with no/mild fibrosis. By HCV genotype, 15:45–17:15 98% (49/50) with GT-1b, 93% (13/14) with GT-2, 94% (179/190) with GT-3, and a single patient with GT-6 achieved SVR. Baseline NS5A RAS were detected in 13% (33/257) of patients. SVR was achieved in 85% (28/33) of patients with NS5A RAS: 100% (6/6) GT-1b patients PL001 with L31 M or Y93H, 75% (3/4) GT-2 with L31 M, 82% (18/22) of GT- 3 with A30 K or Y93H (including all of 8 with no/mild fibrosis), and in Impact of baseline NS5A polymorphisms on sustained virologic the single GT-6 patient with R30S. NS5A RAS were detected at relapse response rates to treatment with daclatasvir plus sofosbuvir in all

Journal

Hepatology InternationalSpringer Journals

Published: Feb 2, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial